FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CADILAHC

576.65
-22.1 (-3.69%)
Updated 03:29 28/07 IST

CADILAHC Buy or Sell - FrontPage Forums

6 Users have submitted 17 trade ideas of Rs. 3,187,323.2 for CADILAHC
Disclaimer
100% Bullish
0% Bearish

CADILAHC Buy or Sell - Brokerage Reports

No. of reports in last year
5
No. of analysts
4
Average Consensus Forecast
472.6
Consensus Potential
-29.20%
See CADILAHC Share Price Targets >>

CADILAHC Ratings

Long term CADILAHC rating by FrontPage users
4.3/5 (7 Ratings)
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?

  1. Home
  2. CADILAHC Forum

CADILAHC Share Price Discussion


BTST OPTION CALL:

#CADILAHC 560 PE AUG BUY >>>> @13.45
Like
Reply (1)
See all replies

At what level one should enter for investment
R
Reputation: 0 • Today 8:03 AM

Type
Sell
Instrument
CADILAHC AUG21 FUT
Entry Price
₹585
Price@Trade
₹584.15
Target Price
₹570
Stop Price
₹590
Valid Till
Jul 28, 2021 3:20 AM
Margin
₹336,707.25 approx for 2200 Qty
Status
Exited
Exit Price
₹581.9
Net P&L
+₹6,820 (+2.03%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Today 8:04 AM

Update
Trade Entered
Entry Price
₹585
Raj @raj-BJzUrFGqO
Today 8:06 AM

Update
Exited
Exit Price
₹581.9
Net P&L
+₹6,820 (+2.03%)
R
Reputation: 0 • Today 7:15 AM

Type
Buy
Instrument
CADILAHC AUG21 FUT
Entry Price
₹585.45
Price@Trade
₹585.45
Target Price
₹590
Stop Price
₹584
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹337,803.13 approx for 2200 Qty
Status
Exited
Exit Price
₹586.25
Net P&L
+₹1,760 (+0.52%)
Like
Reply (1)
swap_vert
Trade
See all replies
Raj @raj-BJzUrFGqO
Today 7:51 AM

Update
Exited
Exit Price
₹586.25
Net P&L
+₹1,760 (+0.52%)

Type
Sell
Instrument
CADILAHC AUG21 FUT
Entry Price
₹583.85
Price@Trade
₹583.85
Target Price
₹540
Stop Price
₹602
Valid Till
Aug 26, 2021 3:20 AM
Margin
₹335,405.13 approx for 2200 Qty
Status
Exited
Exit Price
₹578.95
Net P&L
+₹10,780 (+3.21%)
Like
Reply (1)
swap_vert
Trade
See all replies
Rohil Lavingia @rohildl
Today 8:47 AM

Update
Exited
Exit Price
₹578.95
Net P&L
+₹10,780 (+3.21%)
S
Reputation: 4,072 • Today 3:13 AM

28-07-21 Intraday SELL CADILAHC in cash
only below 591
Like
Reply (3)
See all replies
Sameer  @tradingfab
Today 3:18 AM

low 587.45 🔥🔥🔥🤑🤑🤑🤑
Sameer  @tradingfab
Today 3:55 AM

low 583.55 🔥🔥🔥🤑🤑🤑
Sameer  @tradingfab
Today 4:14 AM

low 580🔥🔥🔥🤑🤑🤑

Type
Buy
Instrument
CADILAHC
Entry Price
₹596
Price@Trade
₹593.6
Target Price
₹620
Stop Price
₹582
Valid Till
Jul 28, 2021 3:20 AM  Aug 18, 2021 3:20 AM
Margin
₹596,000 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹582
Net P&L
-₹14,000 (-2.35%)
Like
Reply (3)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Today 2:59 AM

Update
Trade Entered
Entry Price
₹596

Update
Time Extended
Price @ Update
₹589.25
Original Time
Jul 28, 2021 3:20 AM
New Time
Aug 18, 2021 3:20 AM
TrackerBot @trackerbot
Today 4:02 AM

Update
Stoploss Hit
Exit Price
₹582
N
Reputation: 15,707 • Today 5:36 AM
Covid-19: Government hopeful of vaccine for 12+ kids soon
India would have 150 million vaccine doses available in August –– a 20-25% jump in vaccine supply over the previous months.
The Economic Times
Like
Reply

Type
Buy
Instrument
CADILAHC
Entry Price
₹598
Price@Trade
₹597.9
Target Price
₹670
Stop Price
₹550
Valid Till
Aug 27, 2021 3:20 AM
Margin
₹179,400 approx for 300 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:17 AM

Update
Trade Entered
Entry Price
₹598

Type
Buy
Instrument
CADILAHC AUG21 FUT
Entry Price
₹586
Price@Trade
₹593.95
Target Price
₹686
Stop Price
₹486
Valid Till
Aug 3, 2021 3:20 AM
Margin
₹343,843.5 approx for 2200 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Today 3:53 AM

Update
Trade Entered
Entry Price
₹586

Type
Buy
Instrument
CADILAHC AUG21 FUT
Entry Price
₹596
Price@Trade
₹594.75
Target Price
₹696
Stop Price
₹496
Valid Till
Aug 3, 2021 3:20 AM
Margin
₹321,409 approx for 2200 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:24 AM

Update
Trade Entered
Entry Price
₹596

Type
Buy
Instrument
CADILAHC JUL21 600 CE
Entry Price
₹8  ₹9.45
Price@Trade
₹9.45
Target Price
₹10.5
Stop Price
₹6.75  ₹8
Valid Till
Jul 27, 2021 3:20 AM
Margin
₹20,790 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
8.0
Net P&L
-₹3,190 (-15.34%)
Like
Reply (4)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:07 AM

Update
Trade Entered
Entry Price
₹9.45
Parag Asija @paragasija
Yesterday 7:07 AM

Update
Stoploss Trailed
Price @ Update
₹9.45
Original SL
₹6.75
New SL
8.0
TrackerBot @trackerbot
Yesterday 7:25 AM

Update
Stoploss Hit
Exit Price
8.0

Type
Buy
Instrument
CADILAHC AUG21 FUT
Entry Price
₹599  ₹604.4
Price@Trade
₹603
Target Price
₹699
Stop Price
₹499
Valid Till
Aug 3, 2021 3:20 AM
Margin
₹325,767.2 approx for 2200 Qty
Status
Active
Like
Reply (2)
swap_vert
Trade
See all replies
Efx Technicals @efx
Yesterday 6:53 AM

Update
Entry Price Modified
Price @ Update
₹604.4
Original Entry Price
₹599
New Entry Price
₹604.4
TrackerBot @trackerbot
Yesterday 6:54 AM

Update
Trade Entered
Entry Price
₹604.4

Type
Buy
Instrument
CADILAHC
Entry Price
₹602
Price@Trade
₹601.85
Target Price
₹605
Stop Price
₹598
Valid Till
Jul 27, 2021 3:20 AM
Margin
₹602,000 approx for 1000 Qty
Status
Target Achieved
Exit Price
₹605
Net P&L
+₹3,000 (+0.5%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:40 AM

Update
Trade Entered
Entry Price
₹602
TrackerBot @trackerbot
Yesterday 6:45 AM

Update
Target Achieved
Exit Price
₹605

Type
Sell
Instrument
CADILAHC
Entry Price
₹602.8
Price@Trade
₹602.8
Target Price
₹588
Stop Price
₹607
Valid Till
Jul 27, 2021 3:20 AM
Margin
₹18,084 approx for 30 Qty
Status
Stoploss Hit
Exit Price
₹607
Net P&L
-₹126 (-0.7%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:55 AM

Update
Stoploss Hit
Exit Price
₹607

Type
Sell
Instrument
CADILAHC JUL21 FUT
Entry Price
₹599.25
Price@Trade
₹599.25
Target Price
₹570
Stop Price
₹605
Valid Till
Jul 28, 2021 3:20 AM
Margin
₹326,100.5 approx for 2200 Qty
Status
Validity Over
Exit Price
₹577
Net P&L
+₹48,950 (+15.01%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Today 8:50 AM

Update
Validity Over
Exit Price
₹577
Net P&L
+₹48,950 (+15.01%)

Type
Sell
Instrument
CADILAHC AUG21 600 PE
Entry Price
₹14.85  ₹15.25
Price@Trade
₹15.3
Target Price
₹10
Stop Price
₹15.5
Valid Till
Jul 27, 2021 3:20 AM
Margin
₹353,896.4 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹15.5
Net P&L
-₹550 (-0.16%)
Like
Reply (3)
swap_vert
Trade
See all replies
Abhishek kumar @abisek8
Yesterday 3:57 AM

Update
Entry Price Modified
Price @ Update
₹15.25
Original Entry Price
₹14.85
New Entry Price
₹15.25
TrackerBot @trackerbot
Yesterday 3:58 AM

Update
Trade Entered
Entry Price
₹15.25
TrackerBot @trackerbot
Yesterday 4:03 AM

Update
Stoploss Hit
Exit Price
₹15.5

Type
Buy
Instrument
CADILAHC JUL21 630 CE
Entry Price
₹1.9
Price@Trade
₹1.9
Target Price
₹96
Stop Price
₹0
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹4,180 approx for 2200 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
CADILAHC JUL21 620 CE
Entry Price
₹3.45
Price@Trade
₹3.45
Target Price
₹96
Stop Price
₹0
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹37,950 approx for 11000 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
CADILAHC JUL21 620 CE
Entry Price
₹3.4
Price@Trade
₹3.5
Target Price
₹96
Stop Price
₹0
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹149,600 approx for 44000 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 3:45 AM

Update
Trade Entered
Entry Price
₹3.4
Elavarasan in CADILAHC
#CADILAHC Buy abv 619 Tar 625 631 Sl 612.9
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    2-Mar-21Nirmal BangAccumulate470
    8-Feb-21Prabhudas LilladherAccumulate522
    8-Feb-21Dolat CapitalAccumulate503
    7-Nov-20Geojit Financial ServicesBuy511
    3-Nov-20Prabhudas LilladherSell357
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 28595597.65572.85577.35
    Jul 27615622591598.75
    Jul 26615.8615.8603.5605.55
    Jul 23621.4622.5612615.25
    Jul 22625.75630.85616.35620.2
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹630.68
    30 Day Moving Average₹629.76
    50 Day Moving Average₹630.32
    100 Day Moving Average₹567.73
    200 Day Moving Average₹509.89
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    Today 5:36 AM
    Covid-19: Government hopeful of vaccine for 12+ kids soon
    The Economic Times
    NewsBot
    Jul 21 9:46 AM
    Zydus Cadila gets tentative nod from USFDA to market cancer drug
    The Economic Times
    NewsBot
    Jul 15 4:46 AM
    Cadila arm completes sale of animal health business for Rs 2,921 crore
    The Economic Times
    NewsBot
    Jul 2 7:36 AM
    Zydus Cadila gets USFDA nod to market generic HIV infection treatment tablets
    The Economic Times
    NewsBot
    Jun 28 11:36 AM
    Covid cases with variants of concern rose from 10% in May to 51% till June 20: Parliamentary panel told
    The Economic Times
    NewsBot
    Jun 27 11:16 AM
    Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chief
    The Economic Times
    NewsBot
    Jun 24 7:46 AM
    Zydus Cadila gets tentative USFDA nod to market generic sclerosis treatment drug
    The Economic Times
    NewsBot
    Jun 23 5:06 AM
    India likely to have COVID vaccine for children above 2 years by September-October: AIIMS Director
    The Economic Times
    NewsBot
    Jun 23 4:26 AM
    DNA-based coronavirus vaccine: What is it and how does it work?
    The Economic Times
    NewsBot
    Jun 19 1:11 AM
    Zydus to seek emergency nod for Covid vaccine soon
    The Economic Times
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020